Better Buy: Abbott Laboratories vs. Dexcom
Two companies stand at the forefront of the continuous glucose monitoring (CGM) systems market. Abbott Laboratories (NYSE: ABT) has enjoyed tremendous success with its Freestyle Libre CGM. Dexcom (NASDAQ: DXCM) has also seen sales skyrocket for its G6 CGM.
Shares of both companies have performed really well over the past couple of years. But which stock is the better pick for long-term investors now? Here's how Abbott and Dexcom stack up against each other.
Image source: Getty Images.
Source Fool.com
